Skip to main content
    4

    4D Molecular Therapeutics Inc (FDMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.29
    -0.94 (-7.69%)

    Market Cap: $689.52M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    4D Molecular Therapeutics Inc (FDMT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    4D Molecular Therapeutics reported revenue of $85.21M for the fiscal year ended Dec 31, 2025. That year, net income was -$140.11M with a net margin of -164.4%, operating cash flow was -$109.08M and free cash flow was -$109.62M. The quarter ended Sep 30, 2026 had revenue of $4.14M and net income of -$78.06M.

    Revenue and Margins

    Over the 8 years to Dec 2025, revenue grew from $5.79M, a compound annual rate of 40.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$85.21MN/A100.0%-187.2%-164.4%
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$20.72M+562.3%100.0%-544.6%-486.6%
    Dec 2022$3.13M-82.7%100.0%-3516.5%-3435.4%
    Dec 2021$18.04M+32.5%100.0%-395.5%-395.4%
    Dec 2020$13.61M+94.8%100.0%-416.3%-416.5%
    Dec 2019$6.99M-50.6%100.0%-726.7%-705.8%
    Dec 2018$14.13M+144.0%-30.0%-73.6%-67.6%
    Dec 2017$5.79MN/A-134.4%-194.7%-193.8%
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$85.21M$0$20.72M$3.13M$18.04M$13.61M$6.99M$14.13M$5.79M
    Cost of revenue$0$0$0$0$0$0$0$18.36M$13.57M
    Gross profit$85.21M$0$20.72M$3.13M$18.04M$13.61M$6.99M-$4.23M-$7.78M
    Research and development$195.70M$141.30M$97.10M$80.25M$61.36M$53.04M$43.85M$18.36M$13.57M
    Operating income-$159.55M-$187.84M-$112.87M-$110.03M-$71.33M-$56.66M-$50.76M-$10.40M-$11.27M
    Net income-$140.11M-$160.87M-$100.84M-$107.49M-$71.32M-$56.69M-$49.31M-$9.55M-$11.22M
    EBITDA-$156.69MN/A-$108.54M-$105.13M-$67.72M-$55.40M-$49.81M-$9.70M-$10.65M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$4.14M$3.78M$3.05M$85.21M$90.00K$15.00K$0$1.00K$0$0$0$519.00K
    Gross profit$4.14M$3.78M$3.05M$85.21M$90.00K$15.00K$0-$1.78M$0$0$0$519.00K
    Operating income-$81.22M-$77.03M-$73.62M$14.71M-$61.19M-$59.46M-$53.62M-$56.12M-$51.13M-$42.46M-$38.14M-$36.65M
    Net income-$78.06M-$72.94M-$68.76M$19.40M-$56.88M-$54.66M-$47.97M-$49.67M-$43.84M-$34.95M-$32.40M-$32.28M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $5.59M by $54.65M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$566.71M$560.38M$339.89M$261.85M$353.49M$288.33M$58.23M$96.97M$27.32M
    Current assets$413.13M$434.93M$296.59M$220.51M$256.28M$282.66M$52.51M$94.07M$24.50M
    Cash and equivalents$60.24M$149.34M$249.11M$52.35M$153.00M$276.73M$49.65M$91.76M$23.85M
    Total liabilities$61.05M$49.78M$32.06M$30.51M$34.38M$31.94M$28.22M$124.56M$46.91M
    Short-term debt$5.59M$5.64M$3.15M$5.31M$1.23MN/AN/A$93.00K$51.00K
    Shareholder equity$505.66M$510.61M$307.83M$231.34M$319.11M$256.39M-$72.97M-$27.59M-$19.59M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$428.75M$492.62M$512.90M$566.71M$423.98M$473.64M$515.73M$560.38M$604.03M$620.12M$629.88M$339.89M
    Total liabilities$90.81M$84.96M$61.07M$61.05M$55.00M$52.75M$46.01M$49.78M$51.08M$31.78M$29.32M$32.06M
    Cash and equivalents$39.10M$70.37M$72.49M$60.24M$48.55M$77.16M$133.53M$149.34M$187.54M$189.06M$275.59M$249.11M
    Shareholder equity$337.94M$407.66M$451.84M$505.66M$368.98M$420.89M$469.72M$510.61M$552.95M$588.34M$600.56M$307.83M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$109.08M-$134.59M-$75.79M-$86.69M-$69.13M-$50.91M-$36.71M-$16.25M$8.24M
    Capital expenditures$536.00K$3.79M$2.77M$11.54M$9.11M$1.00M$3.20M$414.00K$573.00K
    Free cash flow-$109.62M-$138.37M-$78.56M-$98.22M-$78.24M-$51.91M-$39.91M-$16.67M$7.66M
    Share repurchases$0$0$0$468.00K$0N/A$2.26MN/AN/A
    Investing cash flow-$92.97M-$302.44M$115.72M-$17.05M-$172.68M-$1.00M-$3.20M-$414.00K$7.67M
    Financing cash flow$112.96M$337.25M$156.83M$3.08M$118.09M$278.98M-$2.19M$84.58M$16.00K
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$56.71M-$70.00M-$68.13M$28.55M-$46.50M-$43.38M-$47.76M-$45.86M-$29.39M-$30.24M-$29.09M-$24.65M
    Capital expenditures$49.00KN/A$0$70.00K$91.00K$66.00K$631.00K$949.00K$1.78M$349.00K$710.00K$549.00K
    Free cash flow-$56.76MN/A-$68.13M$28.48M-$46.59M-$43.44M-$48.39M-$46.81M-$31.17M-$30.59M-$29.80M-$25.20M
    Last 12 quarters

    Frequently Asked Questions About FDMT

    What is 4D Molecular Therapeutics' annual revenue?

    4D Molecular Therapeutics reported revenue of $85.21M for the fiscal year ended Dec 31, 2025.

    Is 4D Molecular Therapeutics profitable?

    No. 4D Molecular Therapeutics reported net income of -$140.11M for the fiscal year ended Dec 31, 2025, with a net margin of -164.4%.

    How much free cash flow does FDMT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$109.08M minus capital expenditures of $536.00K produced free cash flow of -$109.62M.

    How much debt does 4D Molecular Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $5.59M and cash and equivalents of $60.24M.

    What is FDMT's profit margin?

    For the fiscal year ended Dec 31, 2025, 4D Molecular Therapeutics reported gross margin of 100.0%, operating margin of -187.2% and net margin of -164.4%.